|
TAF5L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.78869951972649E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.66720001640408E-09 |
| Normal-vs-Stage2 |
2.2884999999917E-05 |
| Normal-vs-Stage3 |
7.61030000129281E-08 |
| Normal-vs-Stage4 |
3.07539999999662E-06 |
| Stage1-vs-Stage2 |
9.971400E-01 |
| Stage1-vs-Stage3 |
6.964800E-01 |
| Stage1-vs-Stage4 |
9.062200E-01 |
| Stage2-vs-Stage3 |
7.995200E-01 |
| Stage2-vs-Stage4 |
9.278400E-01 |
| Stage3-vs-Stage4 |
8.733000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.28979995970025E-09 |
| Normal-vs-AfricanAmerican |
1.718480E-02 |
| Normal-vs-Asian |
4.18579999994506E-06 |
| Caucasian-vs-AfricanAmerican |
1.358610E-01 |
| Caucasian-vs-Asian |
9.305400E-01 |
| AfricanAmerican-vs-Asian |
1.511600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.22199996974859E-09 |
| Normal-vs-Female |
3.41719996743706E-09 |
| Male-vs-Female |
3.555600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.56590000147617E-08 |
| Normal-vs-Age(41-60Yrs) |
1.35019999625285E-08 |
| Normal-vs-Age(61-80Yrs) |
1.03999999945259E-07 |
| Normal-vs-Age(81-100Yrs) |
1.305660E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.670000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.466000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.392000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.742800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.147200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.213600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.502600E-03 |
| Classical-VS-Follicular |
1.68055999999472E-05 |
| Classical-VS-Other |
3.770100E-02 |
| Classical-VS-Normal |
1.06619999995505E-06 |
| Tall-VS-Follicular |
3.583600E-01 |
| Tall-VS-Other |
2.364400E-01 |
| Tall-VS-Normal |
6.29130000318057E-08 |
| Follicular-VS-Other |
5.628000E-01 |
| Follicular-VS-Normal |
4.82079931529711E-11 |
| Other-VS-Normal |
4.789100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.90079951778444E-10 |
| Normal-vs-N1 |
3.69200000016612E-07 |
| N0-vs-N1 |
8.596800E-01 |
|
|
